Abstract
Background Recent work suggests that antihypertensive medications may be useful as repurposed treatments for mood disorders. Using large-scale linked healthcare data we investigated whether certain classes of antihypertensive, such as angiotensin antagonists and calcium channel blockers, were associated with reduced risk of new-onset Major Depressive Disorder (MDD) or bipolar disorder.
Method Two cohorts of patients treated with antihypertensives were identified from Scottish prescribing (2009-2016) and hospital admission (1981-2016) records. Eligibility for cohort membership was determined by receipt of a minimum of four prescriptions for antihypertensives within a 12-month window. One treatment cohort (n=538,730) included patients with no previous history of mood disorder, whereas the other (n=262,278) included those who did. Both cohorts were matched by age, sex and area deprivation to untreated comparators. Associations between antihypertensive treatment and new-onset MDD or bipolar episodes were investigated using Cox regression.
Results For patients without a history of mood disorder, antihypertensives were associated with increased risk of new-onset MDD. For angiotensin antagonist monotherapy, the hazard ratio (HR) for new-onset MDD was 1.17 (95%CI 1.04-1.31). Beta blockers’ association was stronger (HR 2.68; 95%CI 2.45-2.92), possibly indicating pre-existing anxiety. Some classes of antihypertensive were associated with protection against bipolar disorder, particularly angiotensin antagonists (HR 0.46; 95%CI 0.30-0.70). For patients with a past history of mood disorders, all classes of antihypertensives were associated with increased risk of future episodes of MDD.
Conclusions There was no evidence that antihypertensive medications prevented new episodes of MDD but angiotensin antagonists may represent a novel treatment avenue for bipolar disorder.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by The Chief Scientist Office of Scotland award (D.J.S, D.M, J.P.P, S.P., grant number TCS/16/06) and the UK MRC Mental Health Data Pathfinder Award (D.J.S., J.P.P., grant number MC_PC_17217).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Footnotes
Financial support: This project was supported by The Chief Scientist Office of Scotland award (D.J.S, D.M, J.P.P, S.P., grant number TCS/16/06) and the UK MRC Mental Health Data Pathfinder Award (D.J.S., J.P.P., grant number MC_PC_17217).
Conflicts of interest: None.
Data Availability
Data cannot be shared publicly because it includes confidential medical records. Researchers can apply for access by submitting an application to the Public Benefit and Privacy Panel (PBPP) at NHS Scotland ISD.
